Finanziertes Projekt

Coronavirus research

Spanien

The epidemic –now pandemic– of the new coronavirus is advancing at a staggering pace. Fortunately, the scientific studies and evidence on the virus (SARS-CoV-2) and the disease (COVID-19) are also advancing at great speed.  

Finanziert dank:
  • Spender
  • Finanzierte Gesamtsumme
    100%finanziert
    • Nicequest Kunden 28.001€
  • Direkte Empfänger 200

    Diejenigen Personen, die auf natürliche Art direkt von den im Projekt ausgeführten Aktionen begünstigt wurden.

  • Indirekte Empfänger 5.000

    Diejenigen identifizierbaren Personen, die einen potentiellen Effekt von den im Projekt durchgeführten Aktionen erfahren.

ISGlobal

Kostenaufstellung

  • Materialien 28.000€
  • Gesamt 28.000€
28.000€

Beschreibung

Hundreds of thousands of people have been diagnosed with COVID-19. The SARS-CoV-2 virus, named after the pneumonia outbreak that erupted in December 2019 in Wuhan, China, is responsible for the disease. To date, this virus in the Coronaviridae family has spread to many countries, affecting Asia, Africa, Europe and the Americas, and has been declared a pandemic by the World Health Organization.

In addition to mitigating the morbidity and mortality associated with COVID-19, in outbreaks like this, preventing the appearance of so-called "secondary cases" is an essential strategy. These secondary cases refer to people who are infected by direct contact with patients with the disease - health personnel and family members, mainly. In addition to perpetuating the spread of the disease, infection by healthcare professionals poses a serious problem in healthcare settings.

The objective of this project is to break the coronavirus transmission chain by using existing medication. The team led by researchers from the Institute for Global Health (ISGlobal) and the Hospital Clínic will explore the efficacy of medicines already on the market to prevent new infections and protect the population at risk, especially health workers and people who are in contact with cases affected by SARS-CoV-2.

Aktivitäten

  • Test the efficacy of other antiviral drugs onin the market is currently being tested. 
  • Conduct clinical assays to test the efficacy of new treatments.

Wer wird begünstigt?

Patients affected by COVID-19 across the world.

Projektziele

Find medication to prevent new COVID-19 infections and protect the population at risk from already marketed medication

Aktualisierungen und Links

ISGlobal (web)

Diese Seite verwendet Cookies. Wenn Sie weiter surfen, gehen wir davon aus, dass Sie die Verwendung akzeptieren. Mehr Information erhalten.